Therapies for depression in Parkinson's disease

Cochrane Database of Systematic Reviews

Volumn 2010, Issue 1, 2003, Pages

  Ghazi Noori, Shabnam ^a   Chung, Tin Hei ^b   Deane, Katherine ^c   Rickards, Hugh E ^d   Clarke, Carl E ^a  

^a CITY HOSPITAL   (United Kingdom)

^b Institute of Health & Society ^*  (United Kingdom)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

^d BIRMINGHAM AND SOLIHULL MENTAL HEALTH NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 4344703106     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD003465     Document Type: Review

References (59)

1. Andersen J, Aabro E, Gulmann N, Hjelmsted A, Pedersen HE. Anti-depressive treatment in Parkinson's disease A controlled trial of the effect of nortiptyline in patients with Parkinson's disease treated with L-dopa. Acta Neurologica Scandinivica 1980;62(4):210-219. [MEDLINE: 81156072]
2. Andersen J, Aabro E, Gulmann N, Hjelmsted A, Pedersen HE. Anti-depressive treatment in Parkinson's disease. A controlled trial of the effects of nortriptyline in patients with Parkinson's disease treated with L-dopa. Acta Neurologica Scandinavica 1980;62:210-219.
3. Rabey JM, Orlov E, Korczyn AD. Comparison of Fluvoxamine versus Amitriptyline for treatment of depression in Parkinson's disease. Neurology Feb 1996;46:A374.
4. Wermuth L, Sorensen PS, Timm B, Utzon NP, Boas J, Dupont E, Magnussen I, Mikkelsen B, Worm-Petersen J, Lauritzen L, Bayer L, Bech P. Depression in idiopathic Parkinson's disease treated with citalopram- A placebo-controlled trial. Nordic Journal of Psychiatry 1998;52(2):163-169. [Sent by Lundbeck Ltd Pharmaceutical company]
5. Allain H, Cougnard J, Neukirch HC. Selegiline in de novo Parkinsonian patients: The French Selegiline Multicenter trial (FSMT). Acta Neurologica Scandinavica 1991;136 [Supp]:73-78.
6. Allain H, Pollak P, Neukirch HC. Symtomatic effect of selegiline in de novo Parkinsonian patients. The French Selegiline Multicenter Trial. Movement Disorders 1993;8 [Suppl 1]:S36-40.
7. Artemenko AR, Levin II. The phototherapy of Parkinsonism patients [Fototerapiia bol'nykh parkinsonizmom]. Zh Nevropatol Psikhiatr Im S S Korsakova 1996;96(3):63-66.
8. Bedard P, Parkes JD, Marsden CD. Nomifensine in Parkinson's disease. Br. J. Clin Pharmac. 1977;4:187S-190S.
9. Boer BH, Erdman RAM, Onstenk HJVC, Schut JPT. Clomipramine, depression and Parkinson's disease [Clomipramine, depressie en de de ziekte van Pakinson (Dutch)]. TPSYCHIAT 1976;18(7-8):499-509.
10. Burke WJ, Peterson J, Rubin EH. Electroconvulsive therpay in the treatment of combined depression and Parkinson's disease. Psychosomatics 1988;29(3):341-346.
11. Cantello R, Aguggia M, Gilli M, Delsedime M, Cutin I C, Riccio A, Mutani R. Major depression in Parkisnon's disease and the mood response to intravenous methylphenidate: possible role of the "hedonic" dopamine synapse. Journal of Neurology, Neurosurgery and Psychiatry 1989;52:724-731.
12. Carrieri PB, Indaco A, Gentile S, Troisi E, Cmpanella G. S-adenosylmethionine treatment of depression in patients with Parkinson's disease. Current Therapeutic Research 1990;48(1):154-160.
13. Ceravolo R, Nuti A, Piccinni A, Dell'Agnello G, Bellini G, Gambaccini G, Dell'Osso L, Murri L, Bonucelli U. Paroxetine in Parkinson's disease: Effects on motor and depressive symptoms. Neurology 2000;55:1216-1218.
14. Ellgring H, Perleth B, Seiler S, Oertel W. Psychological intervention for Parkinson patients. Movement Disorders 1992;7 [Suppl 1]:102.
15. Fahn S, Chouinard S. Experience with tranylcypromine in early Parkinson's disease. J. Neural Transm 1998;52 [Supp]:49-62.
16. Fischer PA, Baas H. Therapeutic efficacy of R-(-)deprenyl as adjuvant therapy in advanced Parkinsonism. J. Neural Transmission 1987;25 [Supp]:137-147.
17. Foy CML, Graham JM, El-Baghdady A, Sagar HJ. Fluoxetine and depression in patients with idopathic Parkinson's disease. Movement Disorders 1998;13:176.
18. Friedman JH, Caley C. Fluoxetine in Parkinson's disease. Movement Disorders 1992;7 [Suppl 1]:102.
19. Gimenez-Roldan A, Dobato JL, Madteo D. Treatement of depression in Parkinson's disease with moclobemide: a pilot open-study. Parkinsonism and Related Disorders 1997;3(4):219-225. [Sent by Roche]
20. Goetz CG, Tanner CM, Klawans HL. Bupropion in Parkinson's disease. Neurology 1984;34:1092-1094.
21. Hauser RA, Zesiewicz TA. Sertraline for the treatment of depression in Parkinson's disease. Movement Disorders 1997;12(5):756-759.
22. Hietanen MH. Selegiline and cognitive function in Parkinson's disease. Acta Neurologica Scandinavica 1991;84(5):407-410.
23. Indaco A, Carrieri PB. Amitriptyline in the treatment of headache in patients with Parkinson's disease: a double-blind placebo-controlled study. Neurology 1988;38(11):1720-1722. [MEDLINE: 89040549]
24. Laitinen L. Desipramine in treatment of Parkinson's disease. Acta Neurologica Scandinivica 1969;45:544-549.
25. Lees AJ, Shaw KM, Kohout LJ, Stern GM, Elsworth JD, Sandler M, Youdim MBH. Deprenyl in Parkinson's disease. The Lancet 1977, (Oct):791-795.
26. Mally J, Stone TW. Improvement in Parkinsonian symptoms after repetitive transcranial magnetic stimulation. Journal of the Neurological Sciences 1999;162(2):179-184.
27. Mally J, Stone TW. Therapeutic and "dose dependent" effect of repetitive microelectroshock induced by transcranial magnetic stimulation in Parkinson's disease. Journal of Neuroscience Research 1999;57(6):935-940.
28. Meara J, Hobson P. Sertraline for the treatment of depression in Parkinson's disease. Movement Disorders 1998;13(3):622.
29. Meara RJ, Howmick BK, Hobson JP. An open uncontolled study of the use of sertraline in the treatment of depression in Parkinson's disease. Journal of Serotonin Research 1996;4:243-249.
30. Muller V, Mohr B, Rosin R, Pulvermuller F, Muller F, Birbaumer N. Short-term effects of behavioural treatment on movement initiation and postural control in Parkinson's disease: a controlled clinical study. Movement Disorders 1997;12(3):306-314.
31. Park DM, Findley LJ, Teychenne PR. Nomifensine in Parkinsonism. Journal of Clinical Pharmacology 1977;4:185S-186S.
32. Pridmore S, Pollard C. Electroconvulsive therapy in Parkinson's disease: 30 months of follow up. Journal of Neurology, Neurosurgery and Psychiatry 1996;61:693-700.
33. Pridmore S, Yeo PT, Pasha MI. Electroconvulsive therapy for the physical signs of Parkinson's disease without depressive disorders. Journal of Neurology, Neurosurgery and Psychiatry 1995;58:641-642.
34. Rektorova I, Rektor I, Hortova H, Bares M, Ehler E, Fiedler J, Ressner P, Urbanek K, Veliskova J, Svatova J, Kulistak P, Fanfrdlova Z. Depression in Parkinson's disease: an eight-month, randomized, open label, national, multi-centre comparative study of pramipexole and pergolide.
35. Shoulson I. An interim report of the effect of selegiline (L-Deprenyl) on the progression of disability in early Parkinson's disease. Eur Neurol 1992;32 [suppl 1]:46-53.
36. Sieradzan K, Channon S, Ramponi C, Stern GM, Lees AJ, Youdim MBH. The therapeutic potential of mocloemide, a reversible selecive monoamine oxidase A inhibitor in Parkinson's dsease. Jounal of Clinical Psychopharmacology 1995;15(4 [suppl 2]):51S-59S.
37. Steur EN, Ballering LA. Moclobemide and selegeline in the treatment of depression in Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry 1997;63:547.
38. Strang RR. Imipramine in treatment of Parkinsonism: a double-blind placebo study. British Medical Journal 1965;2:33-34.
39. Takats A, Tarczy M, Simo M, Szombathelyi E, Bodrogi A, Karpati R. Moclobemide/aurorix/ treatment in Parkinson's disease with depression. New Trends in Clinical Pharmacology 1994; Vol. 8, issue 1:260. [P-8920]
40. Tamai S, Almeida OP. Nortriptyline for the treatment of depression in progressive supranuclear palsy. J. Am Geriatr Soc 1997;45(8):1033-1034.
41. Tarczy MI, Szombathelyi E. Depression in Parkinson's disease with special regard to anxiety. Experiences with paroxetine treatment. Movement Disorders 1998; Vol. 13, issue Supplement 2:275. [P4.239]
42. Tesei S, Antoninin A, Canesi M, Zecchinell A, Mariani CB, Pezzoli G. Tolerability of paroxetine in Parkinson's disease: a prospective study. Movement Disorders 2000;15(5):986-989.
43. Torun S, Uysal M, Ozdemir G. Moclobemide vs. amineptine in depressed patients with Parkinson's disease. Eur Neurol 1995;2:92.
44. Trappler B, Fiedman S. Treatment of depression in Parkinson's disease in the very old. Journal of Pharmacy Technology 1998;14:110-115.
45. Weddelll RA, Weiser R. A double-blind cross-over placebo-controlled trial of the effects of bromocriptine on psychomotor function, cognition, and mood in de novo patients with Parkinson's disease. Behav Pharmacol 1995;6(1):81-91.
46. Wittgens W, Donath O, Trenckmann U. Treatment of depressive syndromes in Parkinson's disease (PD) with Paroxetine. Movement Disorders 1997; Vol. 12 (Suppl 1):128.
47. Ziegler M, Rondot P. [Activite du piribedil dans la maladie de Parkinson, Etude multicentrique]. La Presse Medicale 1999 (Sept);28(26):1414-1418.
48. Mehta DK (Editor). British National Formulary. 1. London, UK: British Medical Association, March, 2001:186-196.
49. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality reports of parallel-group randomised trials. The Lancet 2001;357:1191-1194.
50. Cummings JL. Depression and Parkinson's disease: a review. American Journal of Psychiatry 1992;149(4):443-454.
51. Diagnostic and statistical manual of mental disorders - (DSM-IV). Fourth. Washington DC: American Psychiatric Association, 1994.
52. EPDA. http://www.shef.ac.uk/misc/groups/epda/parkuk.htm. Internet information.
53. Global Parkinson's Disease Survey. PDGS pamphlet 2000?.
54. Hart L, Middleton RK, Wandres DL. Depression treatment in Parkinson's disease. DICP, The Annals of Pharmacotherapy 1991;25:137-138.
55. Hughers AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. Journal of Neurology, Neurosurgery and Psychiatry 1992;3:181-184.
56. Jimenez-Jimenez FJ, Tejeiro J, Martinez-Junquera G, Cabrera-Valdivia F, Alarcon J, Garcia-Albea E. Parkinsonism exacerbated by paroxetine. Neurology 1994;44:2406.
57. Klaassen T, Verhey FRJ, Sneijders GHJM, de Vet HCW, van Praag HM. Treatment of depression in Parkinson's disease: a meta-analysis. The Journal of Neuropsychiatry and Clinical Neurosciences 1995;7:281-286.
58. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. Acta Psychiatria Scandinivica 1987;76(S1):1-99.
59. Schrag A, Jahanshahi M, Quin N. What contributes to quality of life in patients with Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry 2000;69:308-312.